In the context of CLL treatment, researchers and clinicians are exploring other antigen‐specific CAR T cells, such as CD22 CAR T‐cell therapy, which has advanced into CLL patients clinical trials with promising results and tolerability.20, 57. This evidence concerns the gene CD22 and B-cell chronic lymphocytic leukemia.